Skip to main content
. Author manuscript; available in PMC: 2025 May 1.
Published in final edited form as: Otolaryngol Head Neck Surg. 2024 Feb 28;170(5):1430–1441. doi: 10.1002/ohn.670

Table 7:

Hearing Targeted Early CMV Testing Studies

Reference Number of patients with failed NBHS # Tested for cCMV (% = # tested/# failed NBHS) #cCMV positive (% positive) #SNHL/#cCMV positive (%)
Current Study 11,118 9017 (81.1%) 132 (1.5%) 53/132 (39%)
Fowler et. (2017) 17 999 999 (100%)1 31 (3.1%) 20/31 (65%)
Ari-Even et al (2016)21 200 187 (93.5%) 4 (2.3%) 3/4 (75%)
Williams et al (2014)22 411 404 (98%)2 6 (1.5%) 3/6 (50%)
Beswick et al (2019)23 283 234 (83%) 3 (1.3%) 2/3 (67%)
Diener et al (2017)24 509 234 (61.7%) 14 (6%) 4/14 (67%)
Raynor et al (2021)25 444 38 (8.5%) 2 (5.3%) 2/2 (100%)
Ronner et al (2022)26 891 530 (60%) 8 (1.5%) 3/5 (75%)3
Vancor et al (2019)31 171 171 (100%) 2 (1.2%) 1/2(50%)
Fourgeaud et al (2022)32 236 231 (98%) 2 (0.8%) 2/2 (100%)
Webb et al (2022)33 126 96 (76.2%) 1 (1%) 1/1 (100%)
Yamamoto et al (2020)34 91 91 (100%)1 7 (7.7%) 7/7 (100%)
Stehel et al (2008)88 572 483 (84%) 24 (5%) 16/24 (67%)
Total (Exclude Current Study) 4933 3698 (75%) 104 (2.8%) 64/101 (63.3%)
1

Part of a universal CMV study

2

Testing rate affected by need for parental consent, having them perform the testing and returning samples

3

Approximation based on data presented